Skip to main content
. 2015 May 27;45(3):225–233. doi: 10.4070/kcj.2015.45.3.225

Table 3. Adverse event summary.

Combination (n=43) Valsartan (n=41) Rosuvastatin (n=37) p
Any adverse events 15 11 7
Number of subjects who experienced AEs 10 (23.3 ) 7 (17.1 ) 4 (10.8 ) 0.34
Number of subjects who experienced SAEs 1 (2.3 ) 0 (0 ) 0 (0 ) 1.00

AE: adverse event, SAE: serious adverse event